EUVIMEDEUVIMED entdecken
Crossref

Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series

Mahmoud Gamal Algammal, Mohamed R S B Elgmmal, Abdelrahman Mohamed Yassein Abbas, Mohammed Mostafa Mohammed Marouf, Ahmed Mohamed Saleh, Mostafa M Bahaa, Khlood Mohammad Aldossary, Mostafa Mahmoud Mohamed Ali, Marwa Kamal

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05093-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Mahmoud Gamal Algammal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt. Hauptthemen laut MEDLINE: Mucormycosis, Antifungal Agents, Acute Kidney Injury. Die Arbeit nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucormycosis is a rapidly progressive opportunistic fungal infection associated with high morbidity and mortality, especially in immunocompromised patients. In resource-limited settings, management is further hindered by delayed diagnosis and restricted access to safer antifungal formulations. To evaluate survival and renal outcomes among patients with mucormycosis treated with different antifungal regimens. A retrospective review was conducted on 19 patients diagnosed with mucormycosis. Clinical features, comorbidities, antifungal therapy, complications, and outcomes were analyzed. Patients were categorized into five treatment groups based on antifungal regimens. Survival and renal outcomes, including acute kidney injury (AKI) and renal recovery, were assessed. Most patients were diabetic (94.7%), and 52.6% had concurrent or recent COVID-19 infection. All had paranasal sinus involvement, with orbital or palatal extension in 68.4% and CNS involvement in 42%. AKI developed in 68.4% of cases, more common with traditional amphotericin regimens (75%) than with liposomal amphotericin (33.3%). Among those with AKI, 38.5% recovered, while 53.8% progressed to chronic kidney disease. Hypersensitivity reactions occurred in 31.6%, mainly with traditional amphotericin. Overall survival was 84.2%, and prolonged antifungal therapy (> 40 days) with early surgical debridement improved outcomes. The study highlights a substantial gap between international guidelines and real-world practice in low-resource environments, where inconsistent access to liposomal amphotericin limits optimal management. Nevertheless, with early diagnosis, aggressive surgical intervention, and vigilant renal monitoring, favorable outcomes are achievable even with traditional amphotericin. Improving national antifungal procurement, strengthening stock management, and subsidizing liposomal formulations could significantly enhance mucormycosis care in resource-limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisAntifungal AgentsAcute Kidney InjuryHumansRetrospective StudiesFemaleMaleAmphotericin BMiddle AgedTreatment OutcomeAdultResource-Limited SettingsAgedYoung Adult

Stichwörter der Autor:innen

AKILiposomal amphotericinMucormycosisRenal outcomesRetrospective study

Substanzen

Antifungal AgentsAmphotericin Bliposomal amphotericin B

Autor:innen und Institutionen

  • Internal Medicine Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Critical Care Medicine Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Neurology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Endemic Medicine Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
  • Pharmacy Practice Department, Faculty of Pharmacy, National Mansoura University, Gamasa, Egypt.

Zitieren

APA

Algammal, M. G., Elgmmal, M. R. S. B., Abbas, A. M. Y., Marouf, M. M. M., Saleh, A. M., Bahaa, M. M., Aldossary, K. M., Ali, M. M. M., & Kamal, M. (2026). Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05093-3

Vancouver

Algammal MG, Elgmmal MRSB, Abbas AMY, Marouf MMM, Saleh AM, Bahaa MM, et al. Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05093-3

BibTeX
@article{Algammal2026,
  author = {Algammal, Mahmoud Gamal and Elgmmal, Mohamed R S B and Abbas, Abdelrahman Mohamed Yassein and Marouf, Mohammed Mostafa Mohammed and Saleh, Ahmed Mohamed and Bahaa, Mostafa M and Aldossary, Khlood Mohammad and Ali, Mostafa Mahmoud Mohamed and Kamal, Marwa},
  title = {Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05093-3}
}
Kostenlos starten →